Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: J Thorac Oncol. 2021 May 13;16(8):1392–1402. doi: 10.1016/j.jtho.2021.04.019

Table 1B.

cCRT + Durvalumab Patient Characteristics

Characteristic No. of Patients (%) p – value
KEAP1 / NFE2L2 wt
(n = 48)
KEAP1 / NFE2L mt
(n = 18)
Median age, range 66 (45 – 81) 69 (65 – 85) 0.14

Sex 0.72
 Female 21 (44) 7 (39)
 Male 27 (56) 11 (61)

Performance Status 0.36
 ECOG 0 30 (63) 9 (50)
 ECOG 1 18 (37) 9 (50)

Gross Tumor Volume (cc)
 Median, Range 109.7 (7 – 600.7) 143.4 (13.5 – 392.6) 0.98

Histology 0.39
 Adenocarcinoma 34 (71) 12 (67)
 Squamous Cell 11 (23) 3 (16)
 Other 3 (6) 3 (16)

PDL1 Expression 0.76
 < 1% 15 (31) 6 (33)
 ≥ 1% 24 (50) 10 (56)
 Not available 9 (19) 2 (11)

PDL1 ≥50% 0.41
 < 50% 26 (54) 13 (72)
 ≥ 50% 13 (27) 3 (17)
 Not available 9 (19) 2 (11)

AJCC 8th Overall Stage 0.59
 IIIA 15 (31) 5 (28)
 IIIB 25 (52) 8(44)
 IIIC 8 (17) 5 (28)

Smoking History 0.45
 Yes 45 (94) 18 (100)